• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

New Delhi May 19 Ranbaxy Laboratories has received tentative approval from the US Food and Drug Administration to manufacture and market the generic version of Sanofi-Aventis' anti-allergic drug, Allegra.

The company said in a release that it had received tentative approval for 30 mg, 60 mg and 180 mg strengths of the Fexofenadine Hydrochloride tablets, used in the treatment of allergic rhinitis, or allergy symptoms caused by dust particles, or commonly known as hay fever when caused by pollen.

According to the Gurgaon-based company, the total annual market sales for the drug is estimated at $931 million.

"This product represents a future opportunity for Ranbaxy and will be launched following final approval from the FDA," said Mr Jim Meehan, Vice-President of Sales and Marketing for Ranbaxy Pharmaceuticals Inc, the wholly owned US subsidiary of the company.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Court order allows Dr Trehan to continue at Escorts Heart

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line